Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chinook Therapeutics Inc (NQ: KDNY )

22.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 22.23
Bid (Size) 14.31 (13)
Ask (Size) 23.40 (1)
Prev. Close 22.23
Today's Range 22.23 - 22.23
52wk Range 12.41 - 27.44
Shares Outstanding 65,846,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
 
Via Benzinga
Chinook Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga

Performance

YTD
-12.62%
-12.62%
1 Month
+2.40%
+2.40%
3 Month
-13.60%
-13.60%
6 Month
+20.42%
+20.42%
1 Year
+45.29%
+45.29%

More News

Read More
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Where Chinook Therapeutics Stands With Analysts
Via Benzinga
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
Via Investor's Business Daily
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
Chinook Therapeutics's Return On Capital Employed Insights
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Chinook Secures Orphan Drug Status From European Commission For Kidney Disease Drug
Via Benzinga
Chinook's Kidney Disease Candidate Continues To Show Rapid, Sustained Reductions In Biomarkers
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022
Via Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Via Benzinga
88 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.